BG
HRMY icon

Bellevue Group’s Harmony Biosciences HRMY Stock Holding History

Bellevue Group’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-598,046
Closed -$19.5M – 161
2023
Q1 		$19.5M Buy
598,046
+1,854
+0.3% +$84.4K 0.28% 81
2022
Q4 		$32.9M Sell
596,192
-60,996
-9% -$3.35M 0.44% 66
2022
Q3 		$29.1M Sell
657,188
-44,880
-6% -$2.19M 0.42% 63
2022
Q2 		$34.2M Buy
702,068
+577,107
+462% +$26M 0.48% 61
2022
Q1 		$6.08M Buy
124,961
+3,800
+3% +$155K 0.07% 112
2021
Q4 		$5.17M Sell
121,161
-8,128
-6% -$324K 0.05% 126
2021
Q3 		$4.96M Buy
+129,289
New +$4.16M 0.05% 130

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group's HRMY Position: Q2 2023 in Review

Bellevue Group sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 598,046 shares — an estimated $19.5M sold.

Bellevue Group first reported a position in HRMY in Q3 2021 and held it in 7 quarters. The position peaked at $34.2M in Q2 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Bellevue Group reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Bellevue Group sold 598,046 Harmony Biosciences shares in Q2 2023, an estimated $19.5M.
  • Bellevue Group first reported a position in Harmony Biosciences in Q3 2021 and held it in 7 quarters.
  • Bellevue Group's Harmony Biosciences position peaked at $34.2M in Q2 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.